-
1
-
-
84872091789
-
Heart disease and stroke statistics: 2013 update: a report from the American Heart Association
-
American Heart Association Statistics Committee and Stroke Statistics Subcommittee.
-
Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Magid D, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, Moy CS, Mussolino ME, Nichol G, Paynter NP, Schreiner PJ, Sorlie PD, Stein J, Turan TN, Virani SS, Wong ND, Woo D, Turner MB; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics: 2013 update: a report from the American Heart Association. Circulation 2013;127:e6-245.
-
(2013)
Circulation
, vol.127
-
-
Go, A.S.1
Mozaffarian, D.2
Roger, V.L.3
Benjamin, E.J.4
Berry, J.D.5
Borden, W.B.6
Bravata, D.M.7
Dai, S.8
Ford, E.S.9
Fox, C.S.10
Franco, S.11
Fullerton, H.J.12
Gillespie, C.13
Hailpern, S.M.14
Heit, J.A.15
Howard, V.J.16
Huffman, M.D.17
Kissela, B.M.18
Kittner, S.J.19
Lackland, D.T.20
Lichtman, J.H.21
Lisabeth, L.D.22
Magid, D.23
Marcus, G.M.24
Marelli, A.25
Matchar, D.B.26
McGuire, D.K.27
Mohler, E.R.28
Moy, C.S.29
Mussolino, M.E.30
Nichol, G.31
Paynter, N.P.32
Schreiner, P.J.33
Sorlie, P.D.34
Stein, J.35
Turan, T.N.36
Virani, S.S.37
Wong, N.D.38
Woo, D.39
Turner, M.B.40
more..
-
2
-
-
85047683015
-
Clinical review 141: lipids and atherosclerosis: lessons learned from randomized controlled trials of lipid lowering and other relevant studies
-
Kreisberg RA, Oberman A. Clinical review 141: lipids and atherosclerosis: lessons learned from randomized controlled trials of lipid lowering and other relevant studies. J Clin Endocrinol Metab 2002;87:423-37.
-
(2002)
J Clin Endocrinol Metab
, vol.87
, pp. 423-437
-
-
Kreisberg, R.A.1
Oberman, A.2
-
3
-
-
33749073795
-
Cholesterol sensing, trafficking, and esterification
-
Chang TY, Chang CC, Ohgami N, Yamauchi Y. Cholesterol sensing, trafficking, and esterification. Annu Rev Cell Dev Biol 2006;22:129-57.
-
(2006)
Annu Rev Cell Dev Biol
, vol.22
, pp. 129-157
-
-
Chang, T.Y.1
Chang, C.C.2
Ohgami, N.3
Yamauchi, Y.4
-
4
-
-
0025120211
-
Regulation of the mevalonate pathway
-
Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425-30.
-
(1990)
Nature
, vol.343
, pp. 425-430
-
-
Goldstein, J.L.1
Brown, M.S.2
-
5
-
-
10744221008
-
Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption
-
Altmann SW, Davis HR Jr, Zhu LJ, Yao X, Hoos LM, Tetzloff G, Iyer SP, Maguire M, Golovko A, Zeng M, Wang L, Murgolo N, Graziano MP. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004;303:1201-4.
-
(2004)
Science
, vol.303
, pp. 1201-1204
-
-
Altmann, S.W.1
Davis, H.R.2
Zhu, L.J.3
Yao, X.4
Hoos, L.M.5
Tetzloff, G.6
Iyer, S.P.7
Maguire, M.8
Golovko, A.9
Zeng, M.10
Wang, L.11
Murgolo, N.12
Graziano, M.P.13
-
6
-
-
20444371945
-
The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1)
-
Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, Braun MP, Crona JH, Davis HR Jr, Dean DC, Detmers PA, Graziano MP, Hughes M, Macintyre DE, Ogawa A, O'Neill K A, Iyer SP, Shevell DE, Smith MM, Tang YS, Makarewicz AM, Ujjainwalla F, Altmann SW, Chapman KT, Thornberry NA. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci U S A 2005;102:8132-7.
-
(2005)
Proc Natl Acad Sci U S A
, vol.102
, pp. 8132-8137
-
-
Garcia-Calvo, M.1
Lisnock, J.2
Bull, H.G.3
Hawes, B.E.4
Burnett, D.A.5
Braun, M.P.6
Crona, J.H.7
Davis, H.R.8
Dean, D.C.9
Detmers, P.A.10
Graziano, M.P.11
Hughes, M.12
Macintyre, D.E.13
Ogawa, A.14
O'Neill, K.A.15
Iyer, S.P.16
Shevell, D.E.17
Smith, M.M.18
Tang, Y.S.19
Makarewicz, A.M.20
Ujjainwalla, F.21
Altmann, S.W.22
Chapman, K.T.23
Thornberry, N.A.24
more..
-
7
-
-
84856732297
-
Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor
-
Sainz B Jr, Barretto N, Martin DN, Hiraga N, Imamura M, Hussain S, Marsh KA, Yu X, Chayama K, Alrefai WA, Uprichard SL. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med 2012;18:281-5.
-
(2012)
Nat Med
, vol.18
, pp. 281-285
-
-
Sainz, B.1
Barretto, N.2
Martin, D.N.3
Hiraga, N.4
Imamura, M.5
Hussain, S.6
Marsh, K.A.7
Yu, X.8
Chayama, K.9
Alrefai, W.A.10
Uprichard, S.L.11
-
8
-
-
0030863352
-
Niemann-Pick C1 disease gene: homology to mediators of cholesterol homeostasis
-
Carstea ED, Morris JA, Coleman KG, Loftus SK, Zhang D, Cummings C, Gu J, Rosenfeld MA, Pavan WJ, Krizman DB, Nagle J, Polymeropoulos MH, Sturley SL, Ioannou YA, Higgins ME, Comly M, Cooney A, Brown A, Kaneski CR, Blanchette-Mackie EJ, Dwyer NK, Neufeld EB, Chang TY, Liscum L, Strauss JF 3rd, Ohno K, Zeigler M, Carmi R, Sokol J, Markie D, O'Neill RR, van Diggelen OP, Elleder M, Patterson MC, Brady RO, Vanier MT, Pentchev PG, Tagle DA. Niemann-Pick C1 disease gene: homology to mediators of cholesterol homeostasis. Science 1997;277:228-31.
-
(1997)
Science
, vol.277
, pp. 228-231
-
-
Carstea, E.D.1
Morris, J.A.2
Coleman, K.G.3
Loftus, S.K.4
Zhang, D.5
Cummings, C.6
Gu, J.7
Rosenfeld, M.A.8
Pavan, W.J.9
Krizman, D.B.10
Nagle, J.11
Polymeropoulos, M.H.12
Sturley, S.L.13
Ioannou, Y.A.14
Higgins, M.E.15
Comly, M.16
Cooney, A.17
Brown, A.18
Kaneski, C.R.19
Blanchette-Mackie, E.J.20
Dwyer, N.K.21
Neufeld, E.B.22
Chang, T.Y.23
Liscum, L.24
Strauss, J.F.25
Ohno, K.26
Zeigler, M.27
Carmi, R.28
Sokol, J.29
Markie, D.30
O'Neill, R.R.31
van Diggelen, O.P.32
Elleder, M.33
Patterson, M.C.34
Brady, R.O.35
Vanier, M.T.36
Pentchev, P.G.37
Tagle, D.A.38
more..
-
9
-
-
69449089892
-
Membrane topology of human NPC1L1, a key protein in enterohepatic cholesterol absorption
-
Wang J, Chu BB, Ge L, Li BL, Yan Y, Song BL. Membrane topology of human NPC1L1, a key protein in enterohepatic cholesterol absorption. J Lipid Res 2009;50:1653-62.
-
(2009)
J Lipid Res
, vol.50
, pp. 1653-1662
-
-
Wang, J.1
Chu, B.B.2
Ge, L.3
Li, B.L.4
Yan, Y.5
Song, B.L.6
-
10
-
-
0034637440
-
Topological analysis of Niemann-Pick C1 protein reveals that the membrane orientation of the putative sterol-sensing domain is identical to those of 3-hydroxy-3-methylglutaryl-CoA reductase and sterol regulatory element binding protein cleavage-activating protein
-
Davies JP, Ioannou YA. Topological analysis of Niemann-Pick C1 protein reveals that the membrane orientation of the putative sterol-sensing domain is identical to those of 3-hydroxy-3-methylglutaryl-CoA reductase and sterol regulatory element binding protein cleavage-activating protein. J Biol Chem 2000; 275:24367-74.
-
(2000)
J Biol Chem
, vol.275
, pp. 24367-24374
-
-
Davies, J.P.1
Ioannou, Y.A.2
-
11
-
-
0344953585
-
A defective response to Hedge hog signaling in disorders of cholesterol biosynthesis
-
Cooper MK, Wassif CA, Krakowiak PA, Taipale J, Gong R, Kelley RI, Porter FD, Beachy PA. A defective response to Hedge hog signaling in disorders of cholesterol biosynthesis. Nat Genet 2003;33:508-13.
-
(2003)
Nat Genet
, vol.33
, pp. 508-513
-
-
Cooper, M.K.1
Wassif, C.A.2
Krakowiak, P.A.3
Taipale, J.4
Gong, R.5
Kelley, R.I.6
Porter, F.D.7
Beachy, P.A.8
-
12
-
-
38149068309
-
Purified NPC1 protein: II
-
Infante RE, Radhakrishnan A, Abi-Mosleh L, Kinch LN, Wang ML, Grishin NV, Goldstein JL, Brown MS. Purified NPC1 protein: II. Localization of sterol binding to a 240-amino acid soluble luminal loop. J Biol Chem 2008;283:1064-75.
-
(2008)
Localization of sterol binding to a 240-amino acid soluble luminal loop. J Biol Chem
, vol.283
, pp. 1064-1075
-
-
Infante, R.E.1
Radhakrishnan, A.2
Abi-Mosleh, L.3
Kinch, L.N.4
Wang, M.L.5
Grishin, N.V.6
Goldstein, J.L.7
Brown, M.S.8
-
13
-
-
67549105629
-
Structure of N-terminal domain of NPC1 reveals distinct subdomains for binding and transfer of cholesterol
-
Kwon HJ, Abi-Mosleh L, Wang ML, Deisenhofer J, Goldstein JL, Brown MS, Infante RE. Structure of N-terminal domain of NPC1 reveals distinct subdomains for binding and transfer of cholesterol. Cell 2009;137:1213-24.
-
(2009)
Cell
, vol.137
, pp. 1213-1224
-
-
Kwon, H.J.1
Abi-Mosleh, L.2
Wang, M.L.3
Deisenhofer, J.4
Goldstein, J.L.5
Brown, M.S.6
Infante, R.E.7
-
14
-
-
79953229584
-
Molecular characterization of the NPC1L1 variants identified from cholesterol low absorbers
-
Wang LJ, Wang J, Li N, Ge L, Li BL, Song BL. Molecular characterization of the NPC1L1 variants identified from cholesterol low absorbers. J Biol Chem 2011;286:7397-408.
-
(2011)
J Biol Chem
, vol.286
, pp. 7397-7408
-
-
Wang, L.J.1
Wang, J.2
Li, N.3
Ge, L.4
Li, B.L.5
Song, B.L.6
-
15
-
-
33646564118
-
Cholesterol-regulated translocation of NPC1L1 to the cell surface facilitates free cholesterol uptake
-
Yu L, Bharadwaj S, Brown JM, Ma Y, Du W, Davis MA, Michaely P, Liu P, Willingham MC, Rudel LL. Cholesterol-regulated translocation of NPC1L1 to the cell surface facilitates free cholesterol uptake. J Biol Chem 2006;281:6616-24.
-
(2006)
J Biol Chem
, vol.281
, pp. 6616-6624
-
-
Yu, L.1
Bharadwaj, S.2
Brown, J.M.3
Ma, Y.4
Du, W.5
Davis, M.A.6
Michaely, P.7
Liu, P.8
Willingham, M.C.9
Rudel, L.L.10
-
16
-
-
44349126634
-
The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1
-
Ge L, Wang J, Qi W, Miao HH, Cao J, Qu YX, Li BL, Song BL. The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1. Cell Metab 2008;7:508-19.
-
(2008)
Cell Metab
, vol.7
, pp. 508-519
-
-
Ge, L.1
Wang, J.2
Qi, W.3
Miao, H.H.4
Cao, J.5
Qu, Y.X.6
Li, B.L.7
Song, B.L.8
-
17
-
-
34548148209
-
NPC1L1 Niemann-Pick C1-like 1 mediates sterol-specific unidirectional transport of non-esterified cholesterol in McArdle-RH7777 hepatoma cells
-
Brown JM, Rudel LL, Yu L. NPC1L1 (Niemann-Pick C1-like 1) mediates sterol-specific unidirectional transport of non-esterified cholesterol in McArdle-RH7777 hepatoma cells. Biochem J 2007;406:273-83.
-
(2007)
Biochem J
, vol.406
, pp. 273-283
-
-
Brown, J.M.1
Rudel, L.L.2
Yu, L.3
-
18
-
-
0034655917
-
Evidence for a Niemann-Pick C (NPC) gene family: identification and characterization of NPC1L1
-
Davies JP, Levy B, Ioannou YA. Evidence for a Niemann-Pick C (NPC) gene family: identification and characterization of NPC1L1. Genomics 2000;65:137-45.
-
(2000)
Genomics
, vol.65
, pp. 137-145
-
-
Davies, J.P.1
Levy, B.2
Ioannou, Y.A.3
-
19
-
-
16844376244
-
Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia
-
Davies JP, Scott C, Oishi K, Liapis A, Ioannou YA. Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia. J Biol Chem 2005; 280:12710-20.
-
(2005)
J Biol Chem
, vol.280
, pp. 12710-12720
-
-
Davies, J.P.1
Scott, C.2
Oishi, K.3
Liapis, A.4
Ioannou, Y.A.5
-
20
-
-
4043124013
-
Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis
-
Davis HR Jr, Zhu LJ, Hoos LM, Tetzloff G, Maguire M, Liu J, Yao X, Iyer SP, Lam MH, Lund EG, Detmers PA, Graziano MP, Altmann SW. Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J Biol Chem 2004; 279:33586-92.
-
(2004)
J Biol Chem
, vol.279
, pp. 33586-33592
-
-
Davis, H.R.1
Zhu, L.J.2
Hoos, L.M.3
Tetzloff, G.4
Maguire, M.5
Liu, J.6
Yao, X.7
Iyer, S.P.8
Lam, M.H.9
Lund, E.G.10
Detmers, P.A.11
Graziano, M.P.12
Altmann, S.W.13
-
21
-
-
33947102613
-
The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatin
-
Telford DE, Sutherland BG, Edwards JY, Andrews JD, Barrett PH, Huff MW. The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatin. J Lipid Res 2007;48:699-708.
-
(2007)
J Lipid Res
, vol.48
, pp. 699-708
-
-
Telford, D.E.1
Sutherland, B.G.2
Edwards, J.Y.3
Andrews, J.D.4
Barrett, P.H.5
Huff, M.W.6
-
22
-
-
33846173940
-
Modulation of human Niemann-Pick C1-like 1 gene expression by sterol: role of sterol regulatory element binding protein 2
-
Alrefai WA, Annaba F, Sarwar Z, Dwivedi A, Saksena S, Singla A, Dudeja PK, Gill RK. Modulation of human Niemann-Pick C1-like 1 gene expression by sterol: role of sterol regulatory element binding protein 2. Am J Physiol Gastrointest Liver Physiol 2007;292:G369-76.
-
(2007)
Am J Physiol Gastrointest Liver Physiol
, vol.292
-
-
Alrefai, W.A.1
Annaba, F.2
Sarwar, Z.3
Dwivedi, A.4
Saksena, S.5
Singla, A.6
Dudeja, P.K.7
Gill, R.K.8
-
23
-
-
85047683727
-
HNF1alpha and SREBP2 are important regulators of NPC1L1 in human liver
-
Pramfalk C, Jiang ZY, Cai Q, Hu H, Zhang SD, Han TQ, Eriksson M, Parini P. HNF1alpha and SREBP2 are important regulators of NPC1L1 in human liver. J Lipid Res 2010;51:1354-62.
-
(2010)
J Lipid Res
, vol.51
, pp. 1354-1362
-
-
Pramfalk, C.1
Jiang, Z.Y.2
Cai, Q.3
Hu, H.4
Zhang, S.D.5
Han, T.Q.6
Eriksson, M.7
Parini, P.8
-
24
-
-
42049108629
-
HNF4alpha is a crucial modulator of the cholesterol-dependent regulation of NPC1L1
-
Iwayanagi Y, Takada T, Suzuki H. HNF4alpha is a crucial modulator of the cholesterol-dependent regulation of NPC1L1. Pharm Res 2008;25:1134-41.
-
(2008)
Pharm Res
, vol.25
, pp. 1134-1141
-
-
Iwayanagi, Y.1
Takada, T.2
Suzuki, H.3
-
25
-
-
37249042184
-
Fenofibrate reduces intestinal cholesterol absorption via PPARalpha-dependent modulation of NPC1L1 expression in mouse
-
Valasek MA, Clarke SL, Repa JJ. Fenofibrate reduces intestinal cholesterol absorption via PPARalpha-dependent modulation of NPC1L1 expression in mouse. J Lipid Res 2007;48:2725-35.
-
(2007)
J Lipid Res
, vol.48
, pp. 2725-2735
-
-
Valasek, M.A.1
Clarke, S.L.2
Repa, J.J.3
-
26
-
-
30544438067
-
Niemann-Pick C1 like 1 gene expression is down-regulated by LXR activators in the intestine
-
Duval C, Touche V, Tailleux A, Fruchart JC, Fievet C, Clavey V, Staels B, Lestavel S. Niemann-Pick C1 like 1 gene expression is down-regulated by LXR activators in the intestine. Biochem Biophys Res Commun 2006;340:1259-63.
-
(2006)
Biochem Biophys Res Commun
, vol.340
, pp. 1259-1263
-
-
Duval, C.1
Touche, V.2
Tailleux, A.3
Fruchart, J.C.4
Fievet, C.5
Clavey, V.6
Staels, B.7
Lestavel, S.8
-
27
-
-
33750308356
-
Localization and role of NPC1L1 in cholesterol absorption in human intestine
-
Sane AT, Sinnett D, Delvin E, Bendayan M, Marcil V, Menard D, Beaulieu JF, Levy E. Localization and role of NPC1L1 in cholesterol absorption in human intestine. J Lipid Res 2006;47: 2112-20.
-
(2006)
J Lipid Res
, vol.47
, pp. 2112-2120
-
-
Sane, A.T.1
Sinnett, D.2
Delvin, E.3
Bendayan, M.4
Marcil, V.5
Menard, D.6
Beaulieu, J.F.7
Levy, E.8
-
28
-
-
34247209263
-
Deficiency of Niemann-Pick C1 Like 1 prevents atherosclerosis in ApoE-/- mice
-
Davis HR Jr, Hoos LM, Tetzloff G, Maguire M, Zhu LJ, Graziano MP, Altmann SW. Deficiency of Niemann-Pick C1 Like 1 prevents atherosclerosis in ApoE-/- mice. Arterioscler Thromb Vasc Biol 2007;27:841-9.
-
(2007)
Arterioscler Thromb Vasc Biol
, vol.27
, pp. 841-849
-
-
Davis, H.R.1
Hoos, L.M.2
Tetzloff, G.3
Maguire, M.4
Zhu, L.J.5
Graziano, M.P.6
Altmann, S.W.7
-
29
-
-
23244436716
-
Ezetimibe normalizes metabolic defects in mice lacking ABCG5 and ABCG8
-
Yu L, von Bergmann K, Lutjohann D, Hobbs HH, Cohen JC. Ezetimibe normalizes metabolic defects in mice lacking ABCG5 and ABCG8. J Lipid Res 2005;46:1739-44.
-
(2005)
J Lipid Res
, vol.46
, pp. 1739-1744
-
-
Yu, L.1
von Bergmann, K.2
Lutjohann, D.3
Hobbs, H.H.4
Cohen, J.C.5
-
30
-
-
1442335817
-
Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia
-
Multicenter Sitosterolemia Study Group
-
Salen G, von Bergmann K, Lutjohann D, Kwiterovich P, Kane J, Patel SB, Musliner T, Stein P, Musser B; Multicenter Sitosterolemia Study Group. Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia. Circulation 2004;109: 966-71.
-
(2004)
Circulation
, vol.109
, pp. 966-971
-
-
Salen, G.1
von Bergmann, K.2
Lutjohann, D.3
Kwiterovich, P.4
Kane, J.5
Patel, S.B.6
Musliner, T.7
Stein, P.8
Musser, B.9
-
31
-
-
33646362257
-
Intestinal cholesterol absorption inhibitor ezetimibe added to cholestyramine for sitosterolemia and xanthomatosis
-
Salen G, Starc T, Sisk CM, Patel SB. Intestinal cholesterol absorption inhibitor ezetimibe added to cholestyramine for sitosterolemia and xanthomatosis. Gastroenterology 2006;130: 1853-7.
-
(2006)
Gastroenterology
, vol.130
, pp. 1853-1857
-
-
Salen, G.1
Starc, T.2
Sisk, C.M.3
Patel, S.B.4
-
32
-
-
34447120058
-
Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe
-
Temel RE, Tang W, Ma Y, Rudel LL, Willingham MC, Ioannou YA, Davies JP, Nilsson LM, Yu L. Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J Clin Invest 2007;117:1968-78.
-
(2007)
J Clin Invest
, vol.117
, pp. 1968-1978
-
-
Temel, R.E.1
Tang, W.2
Ma, Y.3
Rudel, L.L.4
Willingham, M.C.5
Ioannou, Y.A.6
Davies, J.P.7
Nilsson, L.M.8
Yu, L.9
-
33
-
-
44849142781
-
Effect of ezetimibe on the prevention and dissolution of cholesterol gallstones
-
Wang HH, Portincasa P, Mendez-Sanchez N, Uribe M, Wang DQ. Effect of ezetimibe on the prevention and dissolution of cholesterol gallstones. Gastroenterology 2008;134:2101-10.
-
(2008)
Gastroenterology
, vol.134
, pp. 2101-2110
-
-
Wang, H.H.1
Portincasa, P.2
Mendez-Sanchez, N.3
Uribe, M.4
Wang, D.Q.5
-
34
-
-
47949108449
-
Ezetimibe prevents cholesterol gallstone formation in mice
-
Zuniga S, Molina H, Azocar L, Amigo L, Nervi F, Pimentel F, Jarufe N, Arrese M, Lammert F, Miquel JF. Ezetimibe prevents cholesterol gallstone formation in mice. Liver Int 2008;28:935-47.
-
(2008)
Liver Int
, vol.28
, pp. 935-947
-
-
Zuniga, S.1
Molina, H.2
Azocar, L.3
Amigo, L.4
Nervi, F.5
Pimentel, F.6
Jarufe, N.7
Arrese, M.8
Lammert, F.9
Miquel, J.F.10
-
35
-
-
19544371758
-
Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions
-
Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, Alton KB. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 2005;44:467-94.
-
(2005)
Clin Pharmacokinet
, vol.44
, pp. 467-494
-
-
Kosoglou, T.1
Statkevich, P.2
Johnson-Levonas, A.O.3
Paolini, J.F.4
Bergman, A.J.5
Alton, K.B.6
-
37
-
-
53149110077
-
Kinetic imaging of NPC1L1 and sterol trafficking between plasma membrane and recycling endosomes in hepatoma cells
-
Petersen NH, Faergeman NJ, Yu L, Wustner D. Kinetic imaging of NPC1L1 and sterol trafficking between plasma membrane and recycling endosomes in hepatoma cells. J Lipid Res 2008;49:2023-37.
-
(2008)
J Lipid Res
, vol.49
, pp. 2023-2037
-
-
Petersen, N.H.1
Faergeman, N.J.2
Yu, L.3
Wustner, D.4
-
38
-
-
0035572836
-
Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice
-
Davis HR Jr, Compton DS, Hoos L, Tetzloff G. Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice. Arterioscler Thromb Vasc Biol 2001;21:2032-8.
-
(2001)
Arterioscler Thromb Vasc Biol
, vol.21
, pp. 2032-2038
-
-
Davis, H.R.1
Compton, D.S.2
Hoos, L.3
Tetzloff, G.4
-
39
-
-
38549168453
-
Effects of ezetimibe, simvastatin, atorvastatin, and ezetimibe-statin therapies on non-cholesterol sterols in patients with primary hypercholesterolemia
-
Assmann G, Kannenberg F, Ramey DR, Musliner TA, Gutkin SW, Veltri EP. Effects of ezetimibe, simvastatin, atorvastatin, and ezetimibe-statin therapies on non-cholesterol sterols in patients with primary hypercholesterolemia. Curr Med Res Opin 2008;24:249-59.
-
(2008)
Curr Med Res Opin
, vol.24
, pp. 249-259
-
-
Assmann, G.1
Kannenberg, F.2
Ramey, D.R.3
Musliner, T.A.4
Gutkin, S.W.5
Veltri, E.P.6
-
40
-
-
4544250506
-
Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia
-
Ezetimibe Study Group
-
Davidson MH, Ballantyne CM, Kerzner B, Melani L, Sager PT, Lipka L, Strony J, Suresh R, Veltri E; Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int J Clin Pract 2004;58:746-55.
-
(2004)
Int J Clin Pract
, vol.58
, pp. 746-755
-
-
Davidson, M.H.1
Ballantyne, C.M.2
Kerzner, B.3
Melani, L.4
Sager, P.T.5
Lipka, L.6
Strony, J.7
Suresh, R.8
Veltri, E.9
-
41
-
-
41649107358
-
Simvastatin with or without ezetimibe in familial hypercholesterolemia
-
ENHANCE Investigators.
-
Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, Visseren FL, Sijbrands EJ, Trip MD, Stein EA, Gaudet D, Duivenvoorden R, Veltri EP, Marais AD, de Groot E; ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358:1431-43.
-
(2008)
N Engl J Med
, vol.358
, pp. 1431-1443
-
-
Kastelein, J.J.1
Akdim, F.2
Stroes, E.S.3
Zwinderman, A.H.4
Bots, M.L.5
Stalenhoef, A.F.6
Visseren, F.L.7
Sijbrands, E.J.8
Trip, M.D.9
Stein, E.A.10
Gaudet, D.11
Duivenvoorden, R.12
Veltri, E.P.13
Marais, A.D.14
de Groot, E.15
-
42
-
-
79959746706
-
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
-
SHARP Investigators
-
Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellstrom B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Gronhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R; SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011;377:2181-92.
-
(2011)
Lancet
, vol.377
, pp. 2181-2192
-
-
Baigent, C.1
Landray, M.J.2
Reith, C.3
Emberson, J.4
Wheeler, D.C.5
Tomson, C.6
Wanner, C.7
Krane, V.8
Cass, A.9
Craig, J.10
Neal, B.11
Jiang, L.12
Hooi, L.S.13
Levin, A.14
Agodoa, L.15
Gaziano, M.16
Kasiske, B.17
Walker, R.18
Massy, Z.A.19
Feldt-Rasmussen, B.20
Krairittichai, U.21
Ophascharoensuk, V.22
Fellstrom, B.23
Holdaas, H.24
Tesar, V.25
Wiecek, A.26
Grobbee, D.27
de Zeeuw, D.28
Gronhagen-Riska, C.29
Dasgupta, T.30
Lewis, D.31
Herrington, W.32
Mafham, M.33
Majoni, W.34
Wallendszus, K.35
Grimm, R.36
Pedersen, T.37
Tobert, J.38
Armitage, J.39
Baxter, A.40
Bray, C.41
Chen, Y.42
Chen, Z.43
Hill, M.44
Knott, C.45
Parish, S.46
Simpson, D.47
Sleight, P.48
Young, A.49
Collins, R.50
more..
-
43
-
-
41149120450
-
Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice
-
Zheng S, Hoos L, Cook J, Tetzloff G, Davis H Jr, van Heek M, Hwa JJ. Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice. Eur J Pharmacol 2008;584:118-24.
-
(2008)
Eur J Pharmacol
, vol.584
, pp. 118-124
-
-
Zheng, S.1
Hoos, L.2
Cook, J.3
Tetzloff, G.4
Davis, H.5
van Heek, M.6
Hwa, J.J.7
-
44
-
-
68049123104
-
Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease
-
Nozaki Y, Fujita K, Yoneda M, Wada K, Shinohara Y, Takahashi H, Kirikoshi H, Inamori M, Kubota K, Saito S, Mizoue T, Masaki N, Nagashima Y, Terauchi Y, Nakajima A. Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease. J Hepatol 2009;51:548-56.
-
(2009)
J Hepatol
, vol.51
, pp. 548-556
-
-
Nozaki, Y.1
Fujita, K.2
Yoneda, M.3
Wada, K.4
Shinohara, Y.5
Takahashi, H.6
Kirikoshi, H.7
Inamori, M.8
Kubota, K.9
Saito, S.10
Mizoue, T.11
Masaki, N.12
Nagashima, Y.13
Terauchi, Y.14
Nakajima, A.15
-
45
-
-
79955018542
-
Ezetimibe decreases SREBP-1c expression in liver and reverses hepatic insulin resistance in mice fed a high-fat diet
-
Muraoka T, Aoki K, Iwasaki T, Shinoda K, Nakamura A, Aburatani H, Mori S, Tokuyama K, Kubota N, Kadowaki T, Terauchi Y. Ezetimibe decreases SREBP-1c expression in liver and reverses hepatic insulin resistance in mice fed a high-fat diet. Metabolism 2011;60:617-28.
-
(2011)
Metabolism
, vol.60
, pp. 617-628
-
-
Muraoka, T.1
Aoki, K.2
Iwasaki, T.3
Shinoda, K.4
Nakamura, A.5
Aburatani, H.6
Mori, S.7
Tokuyama, K.8
Kubota, N.9
Kadowaki, T.10
Terauchi, Y.11
-
46
-
-
77957242914
-
Ezetimibe ameliorates cardiovascular complications and hepatic steatosis in obese and type 2 diabetic db/db mice
-
Fukuda M, Nakamura T, Kataoka K, Nako H, Tokutomi Y, Dong YF, Yasuda O, Ogawa H, Kim-Mitsuyama S. Ezetimibe ameliorates cardiovascular complications and hepatic steatosis in obese and type 2 diabetic db/db mice. J Pharmacol Exp Ther 2010;335:70-5.
-
(2010)
J Pharmacol Exp Ther
, vol.335
, pp. 70-75
-
-
Fukuda, M.1
Nakamura, T.2
Kataoka, K.3
Nako, H.4
Tokutomi, Y.5
Dong, Y.F.6
Yasuda, O.7
Ogawa, H.8
Kim-Mitsuyama, S.9
-
48
-
-
36549013633
-
Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome
-
Deushi M, Nomura M, Kawakami A, Haraguchi M, Ito M, Okazaki M, Ishii H, Yoshida M. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBS Lett 2007;581:5664-70.
-
(2007)
FEBS Lett
, vol.581
, pp. 5664-5670
-
-
Deushi, M.1
Nomura, M.2
Kawakami, A.3
Haraguchi, M.4
Ito, M.5
Okazaki, M.6
Ishii, H.7
Yoshida, M.8
-
49
-
-
33746930302
-
Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease
-
Assy N, Grozovski M, Bersudsky I, Szvalb S, Hussein O. Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease. World J Gastroenterol 2006;12:4369-76.
-
(2006)
World J Gastroenterol
, vol.12
, pp. 4369-4376
-
-
Assy, N.1
Grozovski, M.2
Bersudsky, I.3
Szvalb, S.4
Hussein, O.5
-
50
-
-
57349106472
-
Reduced absorption of saturated fatty acids and resistance to diet-induced obesity and diabetes by ezetimibe-treated and Npc1l1-/- mice
-
Labonte ED, Camarota LM, Rojas JC, Jandacek RJ, Gilham DE, Davies JP, Ioannou YA, Tso P, Hui DY, Howles PN. Reduced absorption of saturated fatty acids and resistance to diet-induced obesity and diabetes by ezetimibe-treated and Npc1l1-/- mice. Am J Physiol Gastrointest Liver Physiol 2008; 295:G776-83.
-
(2008)
Am J Physiol Gastrointest Liver Physiol
, vol.295
-
-
Labonte, E.D.1
Camarota, L.M.2
Rojas, J.C.3
Jandacek, R.J.4
Gilham, D.E.5
Davies, J.P.6
Ioannou, Y.A.7
Tso, P.8
Hui, D.Y.9
Howles, P.N.10
-
51
-
-
78149348442
-
Niemann-Pick C1-Like 1 deletion in mice prevents high-fat diet-induced fatty liver by reducing lipogenesis
-
Jia L, Ma Y, Rong S, Betters JL, Xie P, Chung S, Wang N, Tang W, Yu L. Niemann-Pick C1-Like 1 deletion in mice prevents high-fat diet-induced fatty liver by reducing lipogenesis. J Lipid Res 2010;51:3135-44.
-
(2010)
J Lipid Res
, vol.51
, pp. 3135-3144
-
-
Jia, L.1
Ma, Y.2
Rong, S.3
Betters, J.L.4
Xie, P.5
Chung, S.6
Wang, N.7
Tang, W.8
Yu, L.9
-
52
-
-
77952674608
-
Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet
-
Chan DC, Watts GF, Gan SK, Ooi EM, Barrett PH. Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet. Diabetes Care 2010;33:1134-9.
-
(2010)
Diabetes Care
, vol.33
, pp. 1134-1139
-
-
Chan, D.C.1
Watts, G.F.2
Gan, S.K.3
Ooi, E.M.4
Barrett, P.H.5
-
53
-
-
77954366025
-
Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: an open-label, pilot study
-
Yoneda M, Fujita K, Nozaki Y, Endo H, Takahashi H, Hosono K, Suzuki K, Mawatari H, Kirikoshi H, Inamori M, Saito S, Iwasaki T, Terauchi Y, Kubota K, Maeyama S, Nakajima A. Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: an open-label, pilot study. Hepatol Res 2010;40:613-21.
-
(2010)
Hepatol Res
, vol.40
, pp. 613-621
-
-
Yoneda, M.1
Fujita, K.2
Nozaki, Y.3
Endo, H.4
Takahashi, H.5
Hosono, K.6
Suzuki, K.7
Mawatari, H.8
Kirikoshi, H.9
Inamori, M.10
Saito, S.11
Iwasaki, T.12
Terauchi, Y.13
Kubota, K.14
Maeyama, S.15
Nakajima, A.16
-
54
-
-
77955519012
-
NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease
-
Enjoji M, Machida K, Kohjima M, Kato M, Kotoh K, Matsunaga K, Nakashima M, Nakamuta M. NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease. Lipids Health Dis 2010;9:29.
-
(2010)
Lipids Health Dis
, vol.9
, pp. 29
-
-
Enjoji, M.1
Machida, K.2
Kohjima, M.3
Kato, M.4
Kotoh, K.5
Matsunaga, K.6
Nakashima, M.7
Nakamuta, M.8
-
55
-
-
79953163093
-
Chronic administration of ezetimibe increases active glucagon-like peptide-1 and improves glycemic control and pancreatic beta cell mass in a rat model of type 2 diabetes
-
Yang SJ, Choi JM, Kim L, Kim BJ, Sohn JH, Kim WJ, Park SE, Rhee EJ, Lee WY, Oh KW, Park SW, Kim SW, Park CY. Chronic administration of ezetimibe increases active glucagon-like peptide-1 and improves glycemic control and pancreatic beta cell mass in a rat model of type 2 diabetes. Biochem Biophys Res Commun 2011;407:153-7.
-
(2011)
Biochem Biophys Res Commun
, vol.407
, pp. 153-157
-
-
Yang, S.J.1
Choi, J.M.2
Kim, L.3
Kim, B.J.4
Sohn, J.H.5
Kim, W.J.6
Park, S.E.7
Rhee, E.J.8
Lee, W.Y.9
Oh, K.W.10
Park, S.W.11
Kim, S.W.12
Park, C.Y.13
-
56
-
-
0035462466
-
Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men
-
Northern Sweden Monitoring of Trends and Determinants in Cardiovascular Disease MONICA.
-
Rask E, Olsson T, Soderberg S, Johnson O, Seckl J, Holst JJ, Ahren B; Northern Sweden Monitoring of Trends and Determinants in Cardiovascular Disease (MONICA). Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men. Diabetes Care 2001;24:1640-5.
-
(2001)
Diabetes Care
, vol.24
, pp. 1640-1645
-
-
Rask, E.1
Olsson, T.2
Soderberg, S.3
Johnson, O.4
Seckl, J.5
Holst, J.J.6
Ahren, B.7
-
57
-
-
36549034768
-
Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths
-
Prospective Studies Collaboration
-
Prospective Studies Collaboration, Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, Qizilbash N, Peto R, Collins R. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007;370:1829-39.
-
(2007)
Lancet
, vol.370
, pp. 1829-1839
-
-
Lewington, S.1
Whitlock, G.2
Clarke, R.3
Sherliker, P.4
Emberson, J.5
Halsey, J.6
Qizilbash, N.7
Peto, R.8
Collins, R.9
-
58
-
-
78149281356
-
Spiroimidazolidinone NPC1L1 inhibitors
-
Howell KL, DeVita RJ, Garcia-Calvo M, Meurer RD, Lisnock J, Bull HG, McMasters DR, McCann ME, Mills SG. Spiroimidazolidinone NPC1L1 inhibitors. Part 2: structure-activity studies and in vivo efficacy. Bioorg Med Chem Lett 2010;20:6929-32.
-
(2010)
Part 2: structure-activity studies and in vivo efficacy. Bioorg Med Chem Lett
, vol.20
, pp. 6929-6932
-
-
Howell, K.L.1
DeVita, R.J.2
Garcia-Calvo, M.3
Meurer, R.D.4
Lisnock, J.5
Bull, H.G.6
McMasters, D.R.7
McCann, M.E.8
Mills, S.G.9
|